A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 200 participants.

Also called NCT07215559

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07215559
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Puerto Rico (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07215559. Randomized; double masking; primary purpose treatment. Start 2025-10-16 (actual); primary completion 2027-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Condition
Obesity
Condition
Overweight
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Macupatide
Intervention (Drug)
Eloralintide
Intervention (Drug)
Macupatide Placebo
Intervention (Drug)
Eloralintide Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07215559
Content hash
f190f7c06f0f48753a399aa0778a06876d775642490bc35b623c396342dafb3d